United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs.
It is a $23.6B healthcare company. Revenue grew 2.5% over the last year, it keeps 42¢ of every dollar of sales as profit, and it holds more cash than debt. It trades at 18.0× earnings — in the most expensive third of its own history.
- Website
- unither.com
- Location
- Silver Spring, MD
- Employees
- 1 400
- Sector
- Healthcare
- Founded
- 1996
Skills
Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.
Strong profitability and health; Valuation lags behind.
Valuation49
- P/E vs own history74th pct · 5/25
- FCF yield4.6% · 12/25
- P/S7.5x · 12/25
- EV/EBITDA14.6x · 20/25
Growth70
- Revenue CAGR17.2% · 20/25
- Net income CAGR29.4% · 25/25
- EPS CAGR ~5Y19.3% · 20/25
- Fwd implied growth3.9% · 5/25
Profitability95
- ROIC31.7% · 25/25
- ROE20.2% · 20/25
- Net margin41.6% · 25/25
- Operating margin44.4% · 25/25
Health100
- Altman Z21.46 · 25/25
- Current ratio5.73 · 25/25
- Interest coverage42.2x · 25/25
- Net cash / debtNet cash · 25/25
Quality69
- Piotroski F7/9 · 22/25
- Beneish M-2.63 · 25/25
- FCF conversion83% · 22/25
- Margin stabilityσ 44.4% · 0/25
Moat68
- ROIC >12% years9/10 yrs · 25/25
- Median gross margin92.0% · 25/25
- FCF-positive years9/10 yrs · 18/25
- Worst-year net marginworst -7.2% · 0/25
Experience
The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.
- FY2025FinancialBest year on record$1.33B net income
- 2023AcquisitionUnited Therapeutics Corporation completed the acquisition of Miromatrix Medical Inc., a…
- FY2020FinancialPositive free cash flow every year since6-year streak
- 2018AcquisitionThe company acquired SteadyMed, a medical device company developing injectable therapeutic drugs for…
- FY2016FinancialFirst recorded profitable year$714M net income
- FY2016FinancialRevenue already above $1B$1.60B in first reported year
- 2011AcquisitionUnited Therapeutics acquired Revivicor, a company focused on developing genetic biotechnology platforms to…
- 1996FoundedUnited Therapeutics was founded in 1996 by Martine Rothblatt, an American lawyer, author
Achievements
Verifiable track record, straight from the reported numbers.
Strengths & watch-outs
What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.
Strengths
- High gross margin (86.1%)
- Strongly profitable — 41.6% net margin
- Strong cash conversion — FCF is 34.6% of revenue
- Net cash position after subtracting debt from cash
- Interest covered 42.2× by operating earnings
Watch-outs
- Loss-making in 1 of the recent years
Qualifications
The basics a company should meet before you research it further. Each check uses the reported numbers.
- Revenue growing — the company sells more than a year ago+2.5% YoY
- Profitable — makes more than it spends$1.31B TTM
- Profit growing — earnings are higher than last year+22.9% YoY
- Generates cash — cash left after running and investing$1.09B TTM
- Debt under control — could handle its obligationsmore cash than debt
- Established company — not a micro-cap — lower blow-up risk$23.6B market cap
- Not printing shares — share count not ballooning — you keep your slice+7.4% shares over ~5y
- Proven track record — years of profitability behind it9/10 profitable years
- Financially stable — balance sheet not near distressAltman Z 21.5 — safe
- Pays a dividend — returns cash to shareholdersno data
- Valuation not extreme — price not wildly above earningsP/E 18.0
Peer comparisonUnited Therapeutics Corp vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾Close ▴
| Company | Market cap | P/E | Revenue growth | Net margin | Profile |
|---|---|---|---|---|---|
| UTHR this company | $23.6B | 18.0 | +2.5% | 41.6% | Strong |
| LLY Eli Lilly & Co. | $1.0T | 41.6 | +49.6% | 33.5% | Solid |
| JNJ Johnson & Johnson | $630.9B | 29.9 | +8.1% | 21.5% | Mixed |
| ABBV Abbvie Inc. | $488.5B | 77.4 | +10.4% | 9.8% | Mixed |
| MRK Merck & Co., Inc. | $361.0B | 113.2 | +4.6% | 4.8% | Mixed |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delaware) | $340.7B | 24.1 | +6.5% | 3.1% | Mixed |
| NVS Novartis AG | $273.2B | 20.3 | +9.6% | 24.7% | Solid |
Head-to-head: UTHR vs LLY · UTHR vs JNJ · UTHR vs ABBV
References
What covering analysts publish about the company — information only, not a recommendation.
Appendix · Financial records
The full statements behind this CV, FY2016–FY2025. For readers who want to check the numbers.
Live data and quarterly detail: stockcv.com/UTHR
Want the live picture — intraday moves, valuation history and full analysis?
Deeper analysis of UTHR on PreMarketPriceFigures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $549.16 · market cap $23.6B.